

## **BLNK Antibody (N-term) Blocking peptide**

Synthetic peptide Catalog # BP13433a

## **Specification**

# **BLNK Antibody (N-term) Blocking peptide - Product Information**

**Primary Accession** 

**Q8WV28** 

# BLNK Antibody (N-term) Blocking peptide - Additional Information

**Gene ID 29760** 

#### **Other Names**

B-cell linker protein, B-cell adapter containing a SH2 domain protein, B-cell adapter containing a Src homology 2 domain protein, Cytoplasmic adapter protein, Src homology 2 domain-containing leukocyte protein of 65 kDa, SLP-65, BLNK, BASH, SLP65

### Target/Specificity

The synthetic peptide sequence used to generate the antibody AP13433a was selected from the N-term region of BLNK. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

### **Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

#### Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

#### **Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

### **BLNK Antibody (N-term) Blocking peptide - Protein Information**

**Name BLNK** 

Synonyms BASH, SLP65

### **Function**

Functions as a central linker protein, downstream of the B- cell receptor (BCR), bridging the SYK kinase to a multitude of signaling pathways and regulating biological outcomes of B-cell function and development. Plays a role in the activation of ERK/EPHB2, MAP kinase p38 and JNK. Modulates AP1 activation. Important for the activation of NF-kappa-B and NFAT. Plays an important role in BCR- mediated PLCG1 and PLCG2 activation and Ca(2+) mobilization and is required for trafficking of the BCR to late endosomes. However, does not seem to be required for pre-BCR-mediated activation of MAP kinase and phosphatidyl-inositol 3 (PI3) kinase signaling. May be required for the RAC1-JNK pathway. Plays a critical role in orchestrating the pro-B cell to pre-B cell transition. May play an important role in BCR- induced B-cell apoptosis.



Tel: 858.875.1900 Fax: 858.875.1999

#### **Cellular Location**

Cytoplasm. Cell membrane. Note=BCR activation results in the translocation to membrane fraction

#### **Tissue Location**

Expressed in B-cell lineage and fibroblast cell lines (at protein level). Highest levels of expression in the spleen, with lower levels in the liver, kidney, pancreas, small intestines and colon

# **BLNK Antibody (N-term) Blocking peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

#### Blocking Peptides

BLNK Antibody (N-term) Blocking peptide - Images

#### BLNK Antibody (N-term) Blocking peptide - Background

This gene encodes a cytoplasmic linker or adaptor proteinthat plays a critical role in B cell development. This proteinbridges B cell receptor-associated kinase activation withdownstream signaling pathways, thereby affecting various biologicalfunctions. The phosphorylation of five tyrosine residues isnecessary for this protein to nucleate distinct signaling effectors following B cell receptor activation. Mutations in this gene causehypoglobulinemia and absent B cells, a disease in which the pro- topre-B-cell transition is developmentally blocked. Deficiency inthis protein has also been shown in some cases of pre-B acutelymphoblastic leukemia. Alternatively spliced transcript variantsencoding different isoforms have been found for this gene.

## BLNK Antibody (N-term) Blocking peptide - References

Rose, J.E., et al. Mol. Med. 16 (7-8), 247-253 (2010) :Davila, S., et al. Genes Immun. 11(3):232-238(2010)Oellerich, T., et al. Mol. Cell Proteomics 8(7):1738-1750(2009)Imamura, Y., et al. J. Biol. Chem. 284(15):9804-9813(2009)Li, H., et al. PLoS ONE 4 (7), E6410 (2009):